# MT2018-18: Sleeping Beauty Transposon-Engineered Plasmablasts for Hurler Syndrome Post Allo HSCT

> **NCT04284254** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Masonic Cancer Center, University of Minnesota**

## Conditions studied

- Mucopolysaccharidosis Type IH (MPS IH, Hurler Syndrome)
- Mucopolysaccharidosis Type IH
- MPS IH, Hurler Syndrome

## Interventions

- **DRUG:** Autologous Plasmablasts

## Key facts

- **NCT ID:** NCT04284254
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-12
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study went on hold because more pre-clinical work needs to be done per FDA feedback. However, the study never went off hold and the study team has decided to close this study without opening to enrollment.
- **Last updated:** 2022-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04284254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04284254, "MT2018-18: Sleeping Beauty Transposon-Engineered Plasmablasts for Hurler Syndrome Post Allo HSCT". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04284254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*